|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Dr. Margarete Fischer-Bosch-Institut für Klinische Pharmakologie (IKP) am Robert-Bosch-Krankenhaus (RBK) |
|---|---|
| Information provided by: | Dr. Margarete Fischer-Bosch-Institut für Klinische Pharmakologie (IKP) am Robert-Bosch-Krankenhaus (RBK) |
| ClinicalTrials.gov Identifier: | NCT00454714 |
Purpose
This will be a prospective, phase IIIb, double-blind and randomized trial testing the effect of single dose sildenafil application in patients with coronary vasospasm compared to placebo application. The target variable to be tested is the degree of coronary vasoconstriction in response to intracoronary ACh application (in addition to clinical chest pain) which will be imaged by coronary angiography and measured using quantitative coronary angiography software.
Main objective: Has sildenafil the potency to inhibit the induction of coronary vasospasm by intracoronary ACh-application in patients with proven coronary artery spasm?
Secondary objective: Which degree of coronary vasospasm inhibition can be achieved with sildenafil?
| Condition | Intervention | Phase |
|---|---|---|
|
Coronary Vasospasm |
Drug: single dose Sildenafil Drug: Single dose placebo |
Phase III |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Placebo Control, Parallel Assignment, Efficacy Study |
| Official Title: | Application of Sildenafil in Patients With Documented Coronary Vasospasm to Explore the Pathophysiology of Coronary Vasospasm and the Therapeutic Effect of Sildenafil in Patients Suffering From Coronary Vasospasm |
| Estimated Enrollment: | 26 |
| Study Start Date: | March 2007 |
| Estimated Study Completion Date: | December 2009 |
| Estimated Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
A: Active Comparator
Sildenafil arm
|
Drug: single dose Sildenafil
Application of a single dose Sildenafil
|
|
B: Placebo Comparator
Placebo arm
|
Drug: Single dose placebo
Application of a single dose placebo
|
Coronary artery spasm is an abrupt severe vasoconstrictor response which may occur spontaneously in normal and diseased coronary arteries. It may result in myocardial ischemia and may be provoked by various stimuli such as acetylcholine (ACh). Coronary vasospasm is involved in the pathogenesis of Prinzmetal's angina, acute myocardial infarction or sudden cardiac death due to ventricular arrythmias and chest pain symptoms associated with viral myocarditis.
The precise cellular and molecular mechanisms of coronary vasospasm have not yet been elucidated. The most often suggested but competing explanations for this disease are coronary endothelial dysfunction secondary to impaired nitric oxide production versus coronary smooth muscle cell hyperreactivity with or without additional endothelial dysfunction. As the precise cellular mechanism is currently unknown a large group of people can currently not be treated appropriately despite the use of nitrates and calcium antagonists.
Sildenafil is a phosphodiesterase(PDE)-5 inhibitor approved for the treatment of both erectile dysfunction and pulmonary hypertension. PDE-5 has been shown to be also present and play an important vasomotor role in the coronary vessel wall. Application of the inhibitor sildenafil has been shown to increase the resting coronary artery diameter. Furthermore, atherosclerotic coronary artery segments which vasoconstrict following intracoronary ACh-application vasodilate following the application of sildenafil when ACh-testing is repeated. Other studies are also suggesting an improved endothelial function after sildenafil application for both the coronary and the peripheral vasculature.
Taken together, sildenafil is expected to have a positive effect on coronary vasomotility. Whether sildenafil can totally prevent the occurrence of coronary vasospasm or at least decrease the severity of vasospasm has not been studied so far. Thus, the aim of this study is to analyse the possible anti-spastic effects of sildenafil in patients suffering from coronary vasospasm.
Eligibility| Ages Eligible for Study: | 50 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Germany | |
| Robert-Bosch-Krankenhaus | Recruiting |
| Stuttgart, Germany, 70376 | |
| Contact: Ali Yilmaz, MD 49-711-8101 ext 5587 ali.yilmaz@rbk.de | |
| Study Director: | Udo Sechtem, MD | Robert-Bosch-Krankenhaus Stuttgart |
More Information
| Responsible Party: | Division of Cardiology ( Robert Bosch Hospital ) |
| Study ID Numbers: | RBK091 |
| Study First Received: | March 29, 2007 |
| Last Updated: | May 29, 2008 |
| ClinicalTrials.gov Identifier: | NCT00454714 History of Changes |
| Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
|
Coronary Disease Vasodilator Agents Phosphodiesterase Inhibitors Heart Diseases Myocardial Ischemia Vascular Diseases |
Coronary Vasospasm Sildenafil Cardiovascular Agents Ischemia Coronary Artery Disease |
|
Vasodilator Agents Heart Diseases Molecular Mechanisms of Pharmacological Action Myocardial Ischemia Vascular Diseases Coronary Vasospasm Sildenafil |
Enzyme Inhibitors Cardiovascular Agents Pharmacologic Actions Coronary Disease Phosphodiesterase Inhibitors Therapeutic Uses Cardiovascular Diseases |